IEX •
Healthcare •
Biotechnology •
Quote as of 08/14/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeIEX
Market Capitalization6.43 mln
Float4.16 mln
Earnings Date08/20/2026
EPS
135
Exceptional
P / E
0.01
Anomalous
Piotroski F-Score
2
/ 9
Weak
Relative Strength
92
/ 100
Top performer
Debt / Equity
0.03
Debt-free
ROE
-184
Deeply negative
Business Description
NuCana plc is a UK-based company focused on developing better cancer treatments by using its ProTide technology to improve existing chemotherapy drugs, making them more effective at targeting cancer cells. The company has two main drug candidates currently in clinical trials: NUC-3373, being tested in patients with advanced colorectal cancer and solid tumors, and NUC-7738, being tested in patients with advanced solid tumors. NuCana works with Cardiff ProTides Ltd to identify and develop new drug candidates, and has been operating since 1997 from its headquarters in Edinburgh, Scotland.
